Eli Lilly: 284/288 (98.6%; 95% interval 96.5–99.5%). Novo Nordisk: 242/288 (84.0%; 95% interval 79.4–87.8%).
RESEARCH · Published May 23, 2026 · Updated November 8, 2026
Obesity Drugs Index 2.0: Eli Lilly Leads in AI Answers
AI answers analyzed across ChatGPT, Claude, Gemini and Perplexity
of answers named Eli Lilly, the most-named (284 of 288)
tracked companies named at least once (of 24)
of Google searches showed an AI Overview (57 of 60)
Version 2. This version replaces the first version of this study, first published May 23, 2026. It uses measured counts, so the two versions are not comparable. Version 2 asks 24 questions three times each on ChatGPT, Claude, Gemini and Perplexity (288 answers) and adds Google AI Overviews. Every rate comes with its count and a 95% interval.
What the data shows
Eli Lilly
135/288 (46.9%)
53/288 (18.4%)
57/60 (95%)
56/57 (98.2%)
74/288 (25.7%)
Appearance rate across 288 four-engine answers. The bar is the 95% confidence interval; overlapping bars cannot be told apart at this sample size.
Which brands AI engines name
| # | Name | Named in | Appearance rate | 95% interval |
|---|---|---|---|---|
| 1 | Eli Lilly | 284/288 | 98.6% | 96.5–99.5% |
| 2 | Novo Nordisk | 242/288 | 84.0% | 79.4–87.8% |
| 3 | AstraZeneca | 87/288 | 30.2% | 25.2–35.7% |
| 4 | Pfizer | 71/288 | 24.7% | 20.0–29.9% |
| 5 | Roche | 66/288 | 22.9% | 18.4–28.1% |
| 6 | Amgen | 58/288 | 20.1% | 15.9–25.1% |
| 7 | Boehringer Ingelheim | 52/288 | 18.1% | 14.0–22.9% |
| 8 | Merck | 49/288 | 17.0% | 13.1–21.8% |
| 9 | Johnson & Johnson | 45/288 | 15.6% | 11.9–20.3% |
| 10 | Sanofi | 44/288 | 15.3% | 11.6–19.9% |
| 11 | Ro | 36/288 | 12.5% | 9.2–16.8% |
| 12 | AbbVie | 35/288 | 12.2% | 8.9–16.4% |
| 13 | Viking Therapeutics | 35/288 | 12.2% | 8.9–16.4% |
| 14 | WeightWatchers | 31/288 | 10.8% | 7.7–14.9% |
| 15 | Structure Therapeutics | 29/288 | 10.1% | 7.1–14.1% |
The full list
Own-domain citation is the share of 288 grounded answers that cited the tracked name's own domains (subdomains included). Citation share is of all 2,425 citations.
| # | Brand | Named in | Appearance rate | 95% interval | First mention | Own-domain citation | Citation share |
|---|---|---|---|---|---|---|---|
| 1 | Eli Lilly | 284/288 | 98.6% | 96.5–99.5% | 1.9 | 18.4% (53/288) | 2.6% |
| 2 | Novo Nordisk | 242/288 | 84% | 79.4–87.8% | 2.1 | 8% (23/288) | 1.1% |
| 3 | AstraZeneca | 87/288 | 30.2% | 25.2–35.7% | 4.6 | 1% (3/288) | 0.1% |
| 4 | Pfizer | 71/288 | 24.7% | 20–29.9% | 4.6 | 2.1% (6/288) | 0.2% |
| 5 | Roche | 66/288 | 22.9% | 18.4–28.1% | 4.3 | 0.3% (1/288) | 0% |
| 6 | Amgen | 58/288 | 20.1% | 15.9–25.1% | 5.1 | 0.3% (1/288) | 0% |
| 7 | Boehringer Ingelheim | 52/288 | 18.1% | 14–22.9% | 4.4 | 1.7% (5/288) | 0.2% |
| 8 | Merck | 49/288 | 17% | 13.1–21.8% | 4.9 | 0% (0/288) | 0% |
| 9 | Johnson & Johnson | 45/288 | 15.6% | 11.9–20.3% | 3.4 | 0% (0/288) | 0% |
| 10 | Sanofi | 44/288 | 15.3% | 11.6–19.9% | 4.8 | 0% (0/288) | 0% |
| 11 | Ro | 36/288 | 12.5% | 9.2–16.8% | 2.9 | 6.6% (19/288) | 0.8% |
| 12 | AbbVie | 35/288 | 12.2% | 8.9–16.4% | 4.9 | 0% (0/288) | 0% |
| 13 | Viking Therapeutics | 35/288 | 12.2% | 8.9–16.4% | 5.8 | 1.4% (4/288) | 0.2% |
| 14 | WeightWatchers | 31/288 | 10.8% | 7.7–14.9% | 3.2 | 10.4% (30/288) | 1.3% |
| 15 | Structure Therapeutics | 29/288 | 10.1% | 7.1–14.1% | 6 | 0.7% (2/288) | 0.1% |
| 16 | Biogen | 28/288 | 9.7% | 6.8–13.7% | 2.6 | 2.1% (6/288) | 0.2% |
| 17 | Eisai | 24/288 | 8.3% | 5.7–12.1% | 1.8 | 1.4% (4/288) | 0.2% |
| 18 | Zealand Pharma | 24/288 | 8.3% | 5.7–12.1% | 6.5 | 0% (0/288) | 0% |
| 19 | Hims & Hers | 21/288 | 7.3% | 4.8–10.9% | 5.1 | 2.8% (8/288) | 0.4% |
| 20 | Noom | 21/288 | 7.3% | 4.8–10.9% | 4.4 | 6.3% (18/288) | 0.7% |
| 21 | Found | 15/288 | 5.2% | 3.2–8.4% | 3.9 | 3.8% (11/288) | 0.5% |
| 22 | Mochi Health | 14/288 | 4.9% | 2.9–8% | 5.9 | 0% (0/288) | 0% |
| 23 | Calibrate | 12/288 | 4.2% | 2.4–7.1% | 4.7 | 2.8% (8/288) | 0.3% |
| 24 | Henry Meds | 3/288 | 1% | 0.4–3% | 10 | 0% (0/288) | 0% |
Second table: drug brands
Drug-brand names in 288 four-engine answers. Each drug mention is also credited once per answer to its maker in the main company ranking.
| # | Drug brand | Named answers | Rate | 95% interval | Named first |
|---|---|---|---|---|---|
| 1 | Zepbound | 166/288 | 57.6% | 51.9–63.2% | 50 |
| 2 | Wegovy | 163/288 | 56.6% | 50.8–62.2% | 68 |
| 3 | Mounjaro | 125/288 | 43.4% | 37.8–49.2% | 21 |
| 4 | Ozempic | 118/288 | 41.0% | 35.4–46.7% | 43 |
| 5 | Rybelsus | 77/288 | 26.7% | 22.0–32.1% | 3 |
| 6 | Foundayo | 75/288 | 26.0% | 21.3–31.4% | 18 |
| 7 | Trulicity | 53/288 | 18.4% | 14.4–23.3% | 2 |
| 8 | Saxenda | 50/288 | 17.4% | 13.4–22.2% | 1 |
| 9 | CagriSema | 38/288 | 13.2% | 9.8–17.6% | 12 |
| 10 | LillyDirect | 30/288 | 10.4% | 7.4–14.5% | 2 |
| 11 | Januvia | 26/288 | 9.0% | 6.2–12.9% | 4 |
| 12 | Farxiga | 24/288 | 8.3% | 5.7–12.1% | 3 |
| 13 | Jardiance | 24/288 | 8.3% | 5.7–12.1% | 1 |
| 14 | Leqembi | 24/288 | 8.3% | 5.7–12.1% | 16 |
| 15 | Kisunla | 22/288 | 7.6% | 5.1–11.3% | 8 |
| 16 | NovoCare Pharmacy | 16/288 | 5.6% | 3.4–8.8% | 1 |
The top eight, side by side
| # | Name | Appearance rate | Answers and interval | Other measures |
|---|---|---|---|---|
| 1 | Eli Lilly | 98.6% | 284/288 answers · 95% CI 96.5–99.5% | first-mention position: 1.9; owned-domain citation (53/288): 18.4%; citation share: 2.6% |
| 2 | Novo Nordisk | 84.0% | 242/288 answers · 95% CI 79.4–87.8% | first-mention position: 2.1; owned-domain citation (23/288): 8%; citation share: 1.1% |
| 3 | AstraZeneca | 30.2% | 87/288 answers · 95% CI 25.2–35.7% | first-mention position: 4.6; owned-domain citation (3/288): 1%; citation share: 0.1% |
| 4 | Pfizer | 24.7% | 71/288 answers · 95% CI 20–29.9% | first-mention position: 4.6; owned-domain citation (6/288): 2.1%; citation share: 0.2% |
| 5 | Roche | 22.9% | 66/288 answers · 95% CI 18.4–28.1% | first-mention position: 4.3; owned-domain citation (1/288): 0.3%; citation share: 0% |
| 6 | Amgen | 20.1% | 58/288 answers · 95% CI 15.9–25.1% | first-mention position: 5.1; owned-domain citation (1/288): 0.3%; citation share: 0% |
| 7 | Boehringer Ingelheim | 18.1% | 52/288 answers · 95% CI 14–22.9% | first-mention position: 4.4; owned-domain citation (5/288): 1.7%; citation share: 0.2% |
| 8 | Merck | 17.0% | 49/288 answers · 95% CI 13.1–21.8% | first-mention position: 4.9; owned-domain citation (0/288): 0%; citation share: 0% |
The four engines named the leading names at similar rates.
ChatGPT
72 asked · 72 returned · 72 grounded
Same questions, different answers
Claude
72 asked · 72 returned · 72 grounded
Gemini
72 asked · 72 returned · 72 grounded
Perplexity
72 asked · 72 returned · 72 grounded
Google AI Overviews were captured through 60 U.S. desktop searches and scored only where an overview appeared, so five-engine figures use 288 + 57 = 345 answers.
The fifth engine
Trigger rate: 57 of 60 searches
Google AI Overviews appeared on 57 of 60 searches (95%, CI 86.3–98.3%). The other 3 searches showed no overview. Within the 57 overviews, Eli Lilly was named in 56 (98.2%), Novo Nordisk was named in 42 (73.7%), AstraZeneca was named in 14 (24.6%), Roche was named in 14 (24.6%). jamanetwork.com was the most-cited source, with 35 citations and an appearance in 18 of 57 overviews.
| Five-engine rank | Name | Five-engine rate | Four-engine rank |
|---|---|---|---|
| 1 | Eli Lilly | 98.6% | 1 |
| 2 | Novo Nordisk | 82.3% | 2 |
| 3 | AstraZeneca | 29.3% | 3 |
| 4 | Pfizer | 24.1% | 4 |
| 5 | Roche | 23.2% | 5 |
| 6 | Amgen | 20.9% | 6 |
| 7 | Boehringer Ingelheim | 18.0% | 7 |
| 8 | Merck | 16.8% | 8 |
| 9 | Johnson & Johnson | 14.2% | 9 |
| 10 | Sanofi | 13.6% | 10 |
Who each question surfaces first
Six questions from the set. Each tile uses that question's own four-engine answers as the denominator.
| Question | Leader | Next | AI Overview |
|---|---|---|---|
| Q01 · 12 answers | Eli Lilly 100.0% | Novo Nordisk 100.0%; Roche 25.0% | AI Overview shown on 2 of 3 searches |
| Q02 · 12 answers | Eli Lilly 100.0% | Novo Nordisk 100.0% | AI Overview shown on 3 of 3 searches |
| Q03 · 12 answers | Eli Lilly 100.0% | Novo Nordisk 100.0% | AI Overview shown on 3 of 3 searches |
| Q04 · 12 answers | Novo Nordisk 100.0% | Eli Lilly 100.0%; AstraZeneca 75.0% | AI Overview shown on 3 of 3 searches |
| Q05 · 12 answers | Eli Lilly 100.0% | Novo Nordisk 100.0%; Pfizer 91.7% | AI Overview shown on 3 of 3 searches |
| Q06 · 12 answers | Viking Therapeutics 100.0% | Novo Nordisk 91.7%; Structure Therapeutics 83.3% | AI Overview shown on 3 of 3 searches |
The four engines produced 2,425 citations in total. drugs.com was cited most often, with 99 citations (4.1%) across 74 answers. Next came goodrx.com (64), pmc.ncbi.nlm.nih.gov (57), forbes.com (45), fda.gov (37), healthline.com (37).
Four AI engines · share of 288 grounded answers
Most-cited domains
Google AI Overviews · share of 57 overviews
Citation share by source type
Share of all citations by the type of site cited.
| Source type | Four AI engines (of 2,425 citations) | Google AI Overviews (of 268 citations) |
|---|---|---|
| Other / unclassified | 891 (36.7%) | 76 (28.4%) |
| Company / brand sites | 324 (13.4%) | 23 (8.6%) |
| General news / business press | 275 (11.3%) | 8 (3%) |
| Official / government | 252 (10.4%) | 15 (5.6%) |
| Health publishers | 247 (10.2%) | 22 (8.2%) |
| Community / social | 127 (5.2%) | 48 (17.9%) |
| Research / data providers | 126 (5.2%) | 49 (18.3%) |
| Institutions / trade bodies | 69 (2.8%) | 17 (6.3%) |
| Trade / specialist press | 37 (1.5%) | 3 (1.1%) |
| Review / comparison publishers | 32 (1.3%) | 0 (0%) |
| Reference | 31 (1.3%) | 5 (1.9%) |
| Directories / rankings | 14 (0.6%) | 2 (0.7%) |
How can brands improve their AI visibility?
These steps follow from the measured results above. They describe what the engines cited in this study and are not a guarantee of results.
| Step | What this study measured |
|---|---|
| Put your facts on your own domain. | Eli Lilly's own domains were cited in 18.4% of grounded answers, WeightWatchers' in 10.4% and Novo Nordisk's in 8.0%. |
| Keep your facts accurate on the sites engines cite. | The most-cited sites other than the tracked names' own were drugs.com (in 25.7% of grounded answers), goodrx.com (19.1%), pmc.ncbi.nlm.nih.gov (14.6%), forbes.com (11.5%) and healthline.com (10.8%). General news and business press supplied 11.3% of citations and official and government 10.4%. |
| Check each engine separately. | Gemini named Viking Therapeutics in 22.2% of answers against 5.6% on ChatGPT. ChatGPT named Sanofi in 20.8% of answers against 8.3% on Perplexity. |
| Watch names outside the tracked list. | Wegovy (52 answers), Zepbound (51 answers), Mounjaro (50 answers), Ozempic (50 answers), Rybelsus (35 answers) were named often but were not tracked. |
| Re-run the same questions every month. | Compare counts and intervals, not ranks. The 24 questions are in the appendix. |
What AI answers
Which companies lead these AI answers?
Eli Lilly leads this measured set. Eli Lilly: 284/288 (98.6%; 95% interval 96.5–99.5%). Novo Nordisk: 242/288 (84.0%; 95% interval 79.4–87.8%).
Which company is named first most often?
Eli Lilly was the first company named in 135 of 288 answers, with an average first position of 1.9.
How often do Google AI Overviews appear for these questions?
An overview appeared on 57 of 60 searches (95%, CI 86.3–98.3%). Within those 57 overviews, Eli Lilly was named most often, in 56 (98.2%).
Which sources do the engines cite?
Across 2,425 four-engine citations, drugs.com was cited most (99 citations, in 74 of 288 grounded answers), followed by goodrx.com (64 citations).
Do the four engines agree?
Largely. No tracked name differed by more than 12 points between engines.
How this study was measured
24 questions × 3 runs each × 4 AI engines = 288 answers + 60 Google searches · 57 AI Overviews
24 questions asked three times on each of ChatGPT, Claude, Gemini and Perplexity, measured November 3, 2026. United States, English; Google retrieval uses desktop results. Models: gpt-5-mini, claude-sonnet-5-5, gemini-3.6-flash only, sonar-pro. Google AI Overviews come from DataForSEO, not inferred chat answers. Appearance counts returned text, including ungrounded answers; citation rates use grounded answers. Longer overlapping names suppress shorter ones; First mention is the earliest eligible name order. Own-domain rates include declared domains and subdomains; shared parent scopes may count for multiple names and cannot be summed as unique citations.
| Engine | Model IDs called | Asked | Returned | Grounded |
|---|---|---|---|---|
| ChatGPT | gpt-5-mini | 72 | 72 | 72 |
| Claude | claude-sonnet-5-5 | 72 | 72 | 72 |
| Gemini | gemini-3.6-flash | 72 | 72 | 72 |
| Perplexity | sonar-pro | 72 | 72 | 72 |
| Google AI Overviews | DataForSEO Google SERP (live, advanced) | 60 | 57 shown | 57 |
Own-domain citations count a domain plus all its subdomains, with the same rule in every table.
Definitions
- Appearance rate: answers naming the tracked name ÷ answers returned, with Wilson 95% intervals.
- First mention: average order in which the tracked name first appears (1 = first).
- Own-domain citation: grounded answers citing the tracked name's domains ÷ grounded answers.
- Citation share: citations to the tracked name's domains ÷ all citations.
Limits
- Only 24 tracked companies are ranked; results are not an exhaustive market ranking.
- Only the tracked companies were scored. Untracked names that appeared often were not scored, including Wegovy (52 answers), Zepbound (51 answers), Mounjaro (50 answers), Ozempic (50 answers), Rybelsus (35 answers).
- 348 of 360 planned results were returned. 12 AI Overview lookups were excluded after at most three total attempts.
- 60 successful Google searches: 57 overviews shown; 3 without an overview. Failures are excluded, not scored as zero.
- All returned chat answers had search sources.
- Questions 2, 3 and 10 name Mounjaro, Ozempic, Zepbound and Wegovy, so each of those counts includes up to 12 answers to a question that names it.
- Removing 3 Core questions naming tracked subjects leaves 252 eligible answers. The top two are Eli Lilly (248/252) and Novo Nordisk (218/252); their order does not change.
- Unverified own domains are not available, never zero or guessed. Source types use Company / brand sites only for verified official organisations; other unresolved sites are Other / unclassified.
- Wilson 95% intervals are descriptive; overlapping leading intervals do not establish a sole leader. Measurements do not endorse medical, legal, financial or product claims.
- Covers the companies, branded drugs and telehealth providers named in obesity and type 2 diabetes questions, US market. Drug names are tracked in their own table and also credited to their maker. Status: Lilly's oral GLP-1 orforglipron was approved by the FDA as Foundayo on April 1, 2026. Novo Nordisk's CEO is Maziar Mike Doustdar, and its Wegovy pill launched before Foundayo. This report counts names in AI answers only. It makes no safety, efficacy or prescribing claim, and being named is not an endorsement. Questions are informational, not requests for medical advice. Main ranking: companies (drug makers and telehealth providers), with each drug-brand mention credited to its maker; the title and summary follow the Wilson rule on this company view. Drug brands are shown as a second table.
- Google Shopping links and unresolved google.com/goto redirect links are not counted as cited sources; original URLs remain in the evidence.
- Answers were collected through each engine's API using the model IDs listed in the methodology. The consumer ChatGPT, Claude, Gemini and Perplexity apps can answer differently.
The 24 questions
Questions marked "Core question" are the original study questions, asked word for word. The others are added neutral questions.
| # | Question | Group | Source |
|---|---|---|---|
| 01 | What are the most effective prescription weight-loss medications? | Obesity Drugs Index 2.0 | Core question |
| 02 | Mounjaro vs Ozempic: what is the difference? | Obesity Drugs Index 2.0 | Core question |
| 03 | Zepbound vs Wegovy: which works better for weight loss? | Obesity Drugs Index 2.0 | Core question |
| 04 | Which companies make GLP-1 drugs? | Obesity Drugs Index 2.0 | Core question |
| 05 | Which pharmaceutical companies lead in obesity treatment? | Obesity Drugs Index 2.0 | Core question |
| 06 | What oral weight-loss drugs are in development? | Obesity Drugs Index 2.0 | Core question |
| 07 | Where can I get GLP-1 medication online? | Obesity Drugs Index 2.0 | Core question |
| 08 | What are the leading pharmaceutical companies in the US? | Obesity Drugs Index 2.0 | Core question |
| 09 | Which companies are developing Alzheimer's treatments? | Obesity Drugs Index 2.0 | Core question |
| 10 | How much does Zepbound cost without insurance? | Obesity Drugs Index 2.0 | Core question |
| 11 | What are the newest FDA-approved weight-loss drugs? | Obesity Drugs Index 2.0 | Added question |
| 12 | What medications are used to treat type 2 diabetes? | Obesity Drugs Index 2.0 | Added question |
| 13 | What are the most commonly prescribed GLP-1 drugs for type 2 diabetes? | Obesity Drugs Index 2.0 | Added question |
| 14 | What are the newer types of diabetes medication besides metformin? | Obesity Drugs Index 2.0 | Added question |
| 15 | Are there weight-loss pills that work like GLP-1 injections? | Obesity Drugs Index 2.0 | Added question |
| 16 | Which drug companies have the strongest obesity drug pipelines? | Obesity Drugs Index 2.0 | Added question |
| 17 | What next-generation obesity drugs are in late-stage trials? | Obesity Drugs Index 2.0 | Added question |
| 18 | What are the best telehealth programs for medical weight loss? | Obesity Drugs Index 2.0 | Added question |
| 19 | How do online weight-loss programs prescribe GLP-1 medications? | Obesity Drugs Index 2.0 | Added question |
| 20 | What Alzheimer's drugs have been approved recently? | Obesity Drugs Index 2.0 | Added question |
| 21 | Which pharmaceutical companies have the biggest market value? | Obesity Drugs Index 2.0 | Added question |
| 22 | How much do GLP-1 medications cost per month in the US? | Obesity Drugs Index 2.0 | Added question |
| 23 | Which companies make insulin in the US? | Obesity Drugs Index 2.0 | Added question |
| 24 | What are the main differences between semaglutide and tirzepatide? | Obesity Drugs Index 2.0 | Added question |
About 5W
5W is an independent PR, creative and GEO agency founded in 2003, and we get you in the chatbox. All of our work is done in house, including media relations, site building and content. Learn more about our GEO practice or write to info@5wpr.com.
Full report
Read the PDF
Related
More from the series
Get in touch
Let's build your next chapter.
Tell us what you're working on. A senior strategist will respond within one business day.
- info@5wpr.com
- Phone
- 212.999.5585
- Offices
- Miami · HQ100 SE 2nd Street, Floor 38
Miami, FL 33131Tampa110 South 12th Street
Tampa, FL 33602New York469 7th Avenue, Floor 8
New York, NY 10018


